Canakinumab
Drug Name(s): Ilaris
Class: Biologics
Type: IL-Inhibitor
Used to treat systemic juvenile idiopathic arthritis (JIA), adult-onset Still’s disease, and gout.
Dosage
Form(s): single-use vial
Systemic JIA and adult-onset Still’s disease: Taken every 4 weeks. Dosage is based on body weight.
Gout attack: 150 mg subcutaneously. Patients who require re-treatment should have an interval of at least 12 weeks before the second dose.
Potential Side Effects
Diarrhea; headache; pain, redness or swelling at the injection site; stomachache; upper respiratory infection; urinary tract infection
Be Aware
Like all biologics, this drug suppresses the immune system and may increase your risk of infections. Tell your doctor if you have an active infection. Do not start treatment if you have a serious or recurrent infection (such as pneumonia). You should be tested for tuberculosis before starting this medication. Do not get a live vaccine when taking biologics.
Macrophage activation syndrome (MAS) is a life-threatening disorder that has been reported in some patients with systemic JIA who are taking this drug. MAS symptoms include acute illness with persistent fever, mental status changes, nose and gastrointestinal bleeding, swollen lymph glands, and spleen and liver problems. It requires immediate treatment. This drug should not be taken with TNF inhibitors
